AAAAAA

   
Results: 1-25 | 26-31
Results: 1-25/31
Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia
Authors: Lissoni, P Bucovec, R Bonfanti, A Giani, L Mandelli, A Roselli, MG Rovelli, F Fumagalli, L
Citation: P. Lissoni et al., Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia, J PINEAL R, 30(2), 2001, pp. 123-126
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulatingdendritic cells, IL-12 and endothelin-1
Authors: Lissoni, P Malugani, F Bonfanti, A Bucovec, R Secondino, S Brivio, F Ferrari-Bravo, A Ferrante, R Vigore, L Rovelli, F Mandala, M Viviani, S Fumagalli, L Gardani, GS
Citation: P. Lissoni et al., Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulatingdendritic cells, IL-12 and endothelin-1, J BIOL REG, 15(2), 2001, pp. 140-144
Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients
Authors: Lissoni, P Fumagalli, E Malugani, F Ardizzoia, A Bucovec, R Tancini, G Gardani, GS
Citation: P. Lissoni et al., Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients, J BIOL REG, 15(2), 2001, pp. 163-165
Stimulation of IL-18 secretion by IL-2 in patients with advanced cancer
Authors: Lissoni, P Rovelli, F Vellani, D Malugani, F Bucovec, R Chapovalenko, L Fumagalli, E Gardani, G
Citation: P. Lissoni et al., Stimulation of IL-18 secretion by IL-2 in patients with advanced cancer, INT J B MAR, 16(2), 2001, pp. 146-147
A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic cell carcinoma progressing on interleukin-2 alone
Authors: Lissoni, P Rovelli, F Baiocco, N Tangini, G Fumagalli, L
Citation: P. Lissoni et al., A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic cell carcinoma progressing on interleukin-2 alone, ANTICANC R, 21(1B), 2001, pp. 777-779
Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2
Authors: Lissoni, P Mandala, M Curigliano, G Ferretti, G Moro, C Ardizzoia, A Malugani, F Tancini, G Tisi, E Arrigoni, C Barni, S
Citation: P. Lissoni et al., Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2, ONCOL-BASEL, 60(4), 2001, pp. 308-312
Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease
Authors: Lissoni, P Brivio, F Rovelli, F Fumagalli, G Malugani, F Vaghi, N Secondino, S Bucovec, R Gardani, GS
Citation: P. Lissoni et al., Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease, J BIOL REG, 14(4), 2000, pp. 275-277
Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients
Authors: Brivio, F Lissoni, P Gilardi, R Ferrante, R Vigore, L Curzi, L Uggeri, F Nespoli, A Fumagalli, L
Citation: F. Brivio et al., Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients, J BIOL REG, 14(3), 2000, pp. 200-203
Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer
Authors: Lissoni, P Fugamalli, E Malugani, F Ardizzoia, A Secondino, S Tancini, G Gardani, GS
Citation: P. Lissoni et al., Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer, INT J B MAR, 15(4), 2000, pp. 308-311
Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer
Authors: Bonfanti, A Lissoni, P Bucovec, R Rovelli, F Brivio, F Fumagalli, L
Citation: A. Bonfanti et al., Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer, INT J B MAR, 15(2), 2000, pp. 161-164
Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer
Authors: Lissoni, P Brivio, F Ferrante, R Vigore, L Vaghi, M Fumagalli, E Bucovec, R Malugani, F Fumagalli, L
Citation: P. Lissoni et al., Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer, INT J B MAR, 15(1), 2000, pp. 22-25
Effects of oncological surgery on endothelin-1 secretion in patients with operable gastric cancer
Authors: Ferrari-Bravo, A Franciosi, C Lissoni, P Fumagalli, L Uggeri, F
Citation: A. Ferrari-bravo et al., Effects of oncological surgery on endothelin-1 secretion in patients with operable gastric cancer, INT J B MAR, 15(1), 2000, pp. 56-57
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin
Authors: Lissoni, P Mandala, M Brivio, F
Citation: P. Lissoni et al., Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin, EUR UROL, 38(1), 2000, pp. 115-118
Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia
Authors: Lissoni, P Mandala, M Rovelli, F Casu, M Rocco, F Tancini, G Scardino, E
Citation: P. Lissoni et al., Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia, EUR UROL, 37(5), 2000, pp. 569-572
A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies
Authors: Lissoni, P Bolis, S Brivio, F Fumagalli, L
Citation: P. Lissoni et al., A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies, ANTICANC R, 20(3B), 2000, pp. 2103-2105
Surgery-induced decline in circulating dendritic cells in operable cancer patients: A possible explanation of postoperative immunosuppression
Authors: Brivio, F Gilardi, R Bucocev, R Ferrante, R Rescaldani, R Vigore, L Fumagalli, L Nespoli, A Lissoni, P
Citation: F. Brivio et al., Surgery-induced decline in circulating dendritic cells in operable cancer patients: A possible explanation of postoperative immunosuppression, HEP-GASTRO, 47(35), 2000, pp. 1337-1339
Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients
Authors: Bordin, V Giani, L Meregalli, S Bukovec, R Vaghi, MM Mandala, M Paolorossi, F Ardizzoia, A Tancini, G Barni, S Frigerio, F Fumagalli, L Bordoni, A Valusani, G Di Felice, G Lissoni, P
Citation: V. Bordin et al., Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients, UROL INTERN, 64(1), 2000, pp. 3-8
Pre-operative IL-2 immunoprophylaxis of cancer recurrence: Long-term clinical results of a phase II study in radically operable colorectal cancer
Authors: Brivio, F Lissoni, P Fumagalli, L Girlando, M Marsili, MT Nespoli, A Uggeri, F
Citation: F. Brivio et al., Pre-operative IL-2 immunoprophylaxis of cancer recurrence: Long-term clinical results of a phase II study in radically operable colorectal cancer, ONCOL REP, 6(6), 1999, pp. 1205-1207
Decreased toxicity and increased efficacy of cancer chemotherapy using thepineal hormone melatonin in metastatic solid tumour patients with poor clinical status
Authors: Lissoni, P Barni, S Mandala, M Ardizzoia, A Paolorossi, F Vaghi, M Longarini, R Malugani, F Tancini, G
Citation: P. Lissoni et al., Decreased toxicity and increased efficacy of cancer chemotherapy using thepineal hormone melatonin in metastatic solid tumour patients with poor clinical status, EUR J CANC, 35(12), 1999, pp. 1688-1692
Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: A phase II study
Authors: Lissoni, P Tancini, G Paolorossi, F Mandala, M Ardizzoia, A Malugani, F Giani, L Barni, S
Citation: P. Lissoni et al., Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: A phase II study, J PINEAL R, 26(3), 1999, pp. 169-173
Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease
Authors: Lissoni, P Vigore, L Ferranti, R Bukovec, R Meregalli, S Mandala, M Barni, S Tancini, G Fumagalli, L Giani, L
Citation: P. Lissoni et al., Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease, J BIOL REG, 13(4), 1999, pp. 216-219
Which immunological parameters ave clinically essential to monitor IL-2 cancer immunotherapy?
Authors: Lissoni, P Brivio, F Viviani, S Fumagalli, L
Citation: P. Lissoni et al., Which immunological parameters ave clinically essential to monitor IL-2 cancer immunotherapy?, J BIOL REG, 13(2), 1999, pp. 110-114
Endocrinological study of the dopaminergic regulation of prolactin releasein metastatic breast cancer
Authors: Mandala, M Lissoni, P Ardizzoia, A Barni, S Rovelli, F Confalonieri, G Malugani, F Moro, C Fumagalli, G Giani, L Tancini, G
Citation: M. Mandala et al., Endocrinological study of the dopaminergic regulation of prolactin releasein metastatic breast cancer, TUMORI, 85(6), 1999, pp. 494-497
Peripheral blood natural killer cell increase as a predictor of survival in metastatic cancer patients treated by neuroimmunotherapy with subcutaneous low-dose interleukin-2 plus melatonin
Authors: Smith, RA Dzugan, SA Rafique, S Fumagalli, L Lissoni, P
Citation: Ra. Smith et al., Peripheral blood natural killer cell increase as a predictor of survival in metastatic cancer patients treated by neuroimmunotherapy with subcutaneous low-dose interleukin-2 plus melatonin, INT J IMM T, 15(3-4), 1999, pp. 131-135
Melatonin plus interleukin-2 is more effective as neuroimmunotherapy than melatonin plus somastatin analogs and bromocriptine as polyneuroendocrine therapy in untreatable advanced solid tumor patients
Authors: Lissoni, P Paolorossi, F Mandala, L Fumagalli, L Ardizzoia, A
Citation: P. Lissoni et al., Melatonin plus interleukin-2 is more effective as neuroimmunotherapy than melatonin plus somastatin analogs and bromocriptine as polyneuroendocrine therapy in untreatable advanced solid tumor patients, INT J IMM T, 15(2), 1999, pp. 67-72
Risultati: 1-25 | 26-31